Kagiou, Chrysanthi http://orcid.org/0000-0002-2795-1194
Cisneros, Jose A. http://orcid.org/0000-0003-3679-7878
Farnung, Jakob http://orcid.org/0000-0002-4619-3421
Liwocha, Joanna
Offensperger, Fabian http://orcid.org/0009-0008-4304-2346
Dong, Kevin
Yang, Ka http://orcid.org/0000-0001-8937-7397
Tin, Gary http://orcid.org/0009-0005-1298-3221
Horstmann, Christina S.
Hinterndorfer, Matthias
Paulo, Joao A. http://orcid.org/0000-0002-4291-413X
Scholes, Natalie S. http://orcid.org/0000-0002-1053-4079
Sanchez Avila, Juan http://orcid.org/0000-0002-5920-7618
Fellner, Michaela
Andersch, Florian
Hannich, J. Thomas http://orcid.org/0000-0002-2286-4956
Zuber, Johannes http://orcid.org/0000-0001-8810-6835
Kubicek, Stefan http://orcid.org/0000-0003-0855-8343
Gygi, Steven P. http://orcid.org/0000-0001-7626-0034
Schulman, Brenda A. http://orcid.org/0000-0002-3083-1126
Winter, Georg E. http://orcid.org/0000-0001-6606-1437
Article History
Received: 29 January 2024
Accepted: 18 June 2024
First Online: 26 June 2024
Competing interests
: S.K. and G.E.W. are scientific founders and shareholders of Proxygen and Solgate. G.E.W. is on the Scientific Advisory Board of Nexo Therapeutics. The Winter lab received research funding from Pfizer. B.A.S. is a member of the scientific advisory boards of Proxygen and BioTheryX, and a co-inventor of intellectual property licensed to Cinsano. The remaining authors declare no competing interests.